The controversy surrounding the Food and Drug Administration’s (FDA) stance on the abortion pill mifepristone continues to draw attention, with the recent claim that the agency’s actions endanger patients and undermine doctors. The assertion comes from Alliance Defending Freedom’s (ADF) Kristen Waggoner, who states that the FDA’s removal of safety measures previously deemed necessary for the use of abortion drugs as harmful, citing its negative effects encountered firsthand by doctors and medical professionals.
Her assertion was backed by a recent event in which Erin Hawley from the Alliance Defending Freedom represented doctors and medical associations at a US Supreme Court hearing on March 26. The FDA had apparently removed controls including in-person office visits that were in place to check for ectopic pregnancies, severe bleeding, and life-threatening infections. Waggoner criticised this as making the use of abortion drugs less safe and causing potential harm to patients.
Further controversy rose from the oral arguments at the Supreme Court hearing, where the federal government questioned the right of these doctors to challenge the FDA’s actions. Interestingly, the government reportedly stated no one has the right to question the FDA’s decision, essentially implying that the FDA’s move was untouchable and above the law. Waggoner sees this as a violation of the FDA’s responsibility to keep patients safe and advocates for the right to file lawsuits against such inappropriate conduct.
The ADF has accused the FDA of violating federal law by not conducting adequate tests before making decisions on drug safety, as required by federal law. Waggoner also accused the FDA of relying on studies it acknowledged as inadequate when removing the last remaining in-person visit requirement for those taking the drug.
In the latest development, Danco Laboratories – the manufacturer of mifepristone – conceded that its primary interest in the case is profit. Waggoner maintains that independent of one’s views on abortion, the health of women should not be placed below pharmaceutical profits. She argues for the reinstatement of the removed abortion drug safeguards, emphasising the need for a federal government that prioritises health and well-being.
The continued legal fallout from this issue is encapsulated in the case FDA v. Alliance for Hippocratic Medicine and is a clear testament to the ongoing challenge to balance health concerns and regulations within the legal framework.